Home Cart Sign in  
Chemical Structure| 96574-01-5 Chemical Structure| 96574-01-5

Structure of Salvianolic acid A
CAS No.: 96574-01-5

Chemical Structure| 96574-01-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Salvianolic acid A, a natural product isolated and purified from the root of Salvia miltiorrhiza Bge. with antioxidant and protective activity, significantly improves glucose metabolism and inhibit oxidative injury as well as protect against impaired vascular responsiveness in STZ-induced diabetic rats, inhibits platelet activation via the inhibition of PI3K, and attenuates arterial thrombus formation in vivo, suggesting that it may be developed as a therapeutic agent for the prevention of thrombotic disorders. Salvianolic acid A is also a matrix metalloproteinase-9 inhibitor, can prevents cardiac remodeling in spontaneously hypertensive rats, and inhibits PDGF-BB-activated HSC proliferation, partially through apoptosis induction while exerting no direct cytotoxicity on primary hepatocytes and HSC-T6 cells under experimental concentrations.

Synonyms: Salvianolic Acid; Dan Phenolic Acid A

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Krueger, Nadine ; Kronenberger, Thales ; Xie, Hang ; Rocha, Cheila ; Poehlmann, Stefan ; Su, Haixia , et al.

Abstract: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has forced the development of direct-acting antiviral drugs due to the coronavirus disease 2019 (COVID-19) pandemic. The main protease of SARS-CoV-2 is a crucial enzyme that breaks down polyproteins synthesized from the viral RNA, making it a validated target for the development of SARS-CoV-2 therapeutics. New chem. phenotypes are frequently discovered in natural goods. In the current study, we used a fluorogenic assay to test a variety of natural products for their ability to inhibit SARS-CoV-2 Mpro. Several compounds were discovered to inhibit Mpro at low micromolar concentrations It was possible to crystallize robinetin together with SARS-CoV-2 Mpro, and the X-ray structure revealed covalent interaction with the protease's catalytic Cys145 site. Selected potent mols. also exhibited antiviral properties without cytotoxicity. Some of these powerful inhibitors might be utilized as lead compounds for future COVID-19 research.

Keywords: COVID-19 ; antivirals ; coronavirus ; covalent drugs ; dynamic light scattering ; inhibitors ; main protease ; natural products

Alternative Products

Product Details of Salvianolic acid A

CAS No. :96574-01-5
Formula : C26H22O10
M.W : 494.45
SMILES Code : O=C(O)[C@H](OC(/C=C/C1=CC=C(O)C(O)=C1/C=C/C2=CC=C(O)C(O)=C2)=O)CC3=CC=C(O)C(O)=C3
Synonyms :
Salvianolic Acid; Dan Phenolic Acid A
MDL No. :MFCD08458447
InChI Key :YMGFTDKNIWPMGF-UCPJVGPRSA-N
Pubchem ID :5281793

Safety of Salvianolic acid A

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
C3H10T1/2 adipocytes 80 µM 0, 2, 4, 8 hours To examine the time-course effects of Sal A on UCP-1 expression, results showed that UCP-1 expression significantly increased at 2 h, peaked at 4 h, and returned to basal levels at 8 h Front Pharmacol. 2021 May 28;12:614406
HEK293/ET AR cells 5.7 µM (IC50) 10 min Evaluate the antagonistic effect of Sal A on ET AR, results showed Sal A is a selective ET AR antagonist Int J Mol Sci. 2016 Aug 2;17(8):1244
HepG2 cells 25, 50, 100 µM 12 hours To evaluate the protective effects of Salvianolic acid A against palmitic acid-induced hepatocyte cytotoxicity. Results showed that Salvianolic acid A pretreatment significantly ameliorated palmitic acid-induced cell death. Front Pharmacol. 2020 Nov 30;11:560905
H9c2 cardiomyocytes 5, 10, 20, 40 µM 12 hours To evaluate the protective effects of Salvianolic acid A against palmitic acid-induced cardiomyocyte injury. Results showed that Salvianolic acid A significantly reversed PA-induced cell death, improved mitochondrial membrane potential and intracellular reactive oxygen species levels. Front Pharmacol. 2021 Mar 8;12:627123
HeLa cells 3.14 µM (IC50) 15 min Evaluate the inhibitory effect of Sal A on endogenous ET AR, results showed Sal A partially inhibited ET AR activation Int J Mol Sci. 2016 Aug 2;17(8):1244
HiPS-CMs cells 10 µM 24 hours Evaluate the cytotoxicity of Sal A on hiPS-CMs cells, results showed Sal A had no significant cytotoxicity Int J Mol Sci. 2016 Aug 2;17(8):1244
RAW264.7 cells 15 and 30 µM 24 hours To evaluate the effect of SAA on M2-like TAM polarization, results showed SAA increased the expression levels of CD86, IL-1β, and iNOS, and decreased the expression levels of Arg-1 and CD206. Molecules. 2024 Mar 26;29(7):1469
ARPE-19 cells 20 µM 24 hours To evaluate the cytotoxicity of RGD-PEI/SAA complexes, results showed that low concentrations of SAA (≤20 µM) had no obvious cytotoxic effect, and SAA in nanoparticle form was less toxic than free SAA. J Nanobiotechnology. 2021 Jul 2;19(1):196
Human primary chondrocytes 10, 20, 40, 80 µg/mL 24 hours To evaluate the effect of Salvianolic acid A on cell viability. Results showed no significant cytotoxicity at concentrations ≤80 µg/mL, and SAA significantly suppressed IL-1β-induced inflammatory factors (MMP1, MMP13, ADAMTS-5) expression while promoting collagen II and aggrecan synthesis. Drug Des Devel Ther. 2020 May 8;14:1771-1778
HUVECs 25 µM 24 hours To investigate the effect of Salvianolic acid A on high glucose-induced pyroptosis in endothelial cells. Results showed that SAA inhibited PKM2 Y105 phosphorylation, reduced nuclear translocation of PKM2, thereby suppressing NLRP3 inflammasome activation and endothelial cell pyroptosis. Front Pharmacol. 2022 Nov 8;13:1009229
Mouse chondrocytes 6.25, 12.5, 25 µM 24 hours To evaluate the inhibitory effect of SAA on IL-1β-induced inflammatory response and cartilage matrix degradation. Results showed that SAA significantly inhibited the production of inflammatory mediators (NO, PGE2, TNF-α, IL-6, iNOS, COX-2) induced by IL-1β and reduced the degradation of cartilage matrix. Front Pharmacol. 2020 Jun 3;11:682
HL60 cells 25 µM 24 hours Combination treatment of Sal A and ATO significantly enhanced ATO-induced cytotoxicity Front Pharmacol. 2018 May 9;9:487
K562 cells 25 µM 24 hours Combination treatment of Sal A and ATO significantly enhanced ATO-induced cytotoxicity Front Pharmacol. 2018 May 9;9:487
HepaRG cells 25 µM 24 hours Combination treatment of Sal A and ATO significantly enhanced ATO-induced cytotoxicity Front Pharmacol. 2018 May 9;9:487
SGC7901 cells 25 µM 24 hours Combination treatment of Sal A and ATO significantly enhanced ATO-induced cytotoxicity Front Pharmacol. 2018 May 9;9:487
LX2 cells 25 µM 24 hours To investigate the effect of SalA on PDGF-BB-induced fibrosis and ER stress in LX2 cells, results showed that SalA inhibited ER stress and fibrosis by up-regulating SIRT1 Front Pharmacol. 2018 Nov 5;9:1277
HK-2 cells 3, 10, 30 µM 24 hours To evaluate the inhibitory effect of SAA on LPS-induced inflammatory response in HK-2 cells. Results showed that SAA significantly reduced the secretion of TNF-α and IL-1β and inhibited the activation of NF-κB and p38 MAPK signaling pathways. Acta Pharmacol Sin. 2018 Dec;39(12):1855-1864
H9c2 cells 12.5 µM 24 hours Significantly reduced oxidative stress, ferroptosis and CD36 expression, while increasing p-AMPK Burns Trauma. 2024 Apr 9;12:tkad055
AML12 cells 10 µM 24 hours To evaluate the protective effect of Salvianolic acid A on APAP-induced hepatotoxicity, results showed that Salvianolic acid A significantly increased cell viability and alleviated oxidative stress and inflammation. Antioxidants (Basel). 2023 Apr 3;12(4):870
Primary rat cortical neurons 50 µM 24 hours To evaluate the inhibitory effect of Salvianolic acid A on hemin-induced ferroptosis in primary cortical neurons. Results showed that Salvianolic acid A significantly improved cell viability, reduced intracellular ROS production, decreased MDA and Fe2+ levels, and increased the expression of GSH, XCT, and GPX4. Sci Rep. 2024 May 30;14(1):12427
Human umbilical vein endothelial cells (HUVECs) 0.25 µM and 0.5 µM 24 hours SalA promoted cell viability and proliferation rate, decreased LDH and ROS levels, increased SOD activity, significantly attenuated endothelial senescence, inhibited cell apoptosis, and reversed the increase in LC3 II/I ratio and NLRP3 accumulation. Sci Rep. 2024 May 24;14(1):11931
Human glioma cell line U87 0, 5, 10, 15, 20, 25, 50, 100 µM 24, 48 hours To evaluate the effects of Sal A on the viability, proliferation, migration, invasion, and apoptosis of glioma cells. Results showed that Sal A treatment reduced the viability of U87 cells in a dose-dependent manner, inhibited proliferation, migration, and invasion, and promoted apoptosis. Bioengineered. 2022 May;13(5):11646-11655
Human Vascular Smooth Muscle Cells (HVSMC) 10 µM 4 hours To identify protein targets of SAA, transgelin and actin were identified as direct targets of SAA via LC-MS/MS EBioMedicine. 2018 Nov;37:246-258
H9c2 cardiomyocytes 10 µM 4 hours Sal A pretreatment alleviated ATO-induced mitochondrial structural and functional damage Front Pharmacol. 2018 May 9;9:487
C3H10T1/2 adipocytes 20, 40, 80 µM 4 hours To investigate the effects of Sal A on UCP-1 expression, results showed that Sal A upregulated UCP-1 mRNA and protein levels in a dose-dependent manner Front Pharmacol. 2021 May 28;12:614406
HEK293 cells 2.81 μg/mL 4 hours and 24 hours Evaluate the antagonistic effect of Sal A on DOX-induced renal cytotoxicity, results showed Sal A significantly reduced DOX-induced damage to HEK293 cells J Nanobiotechnology. 2022 Sep 24;20(1):425
HUVEC cells 10 µM 48 hours Evaluate the cytotoxicity of Sal A on HUVEC cells, results showed Sal A had no significant cytotoxicity Int J Mol Sci. 2016 Aug 2;17(8):1244
MCF-7/PTX cells 12 µM 48 hours To evaluate the reversal effect of Salvianolic acid A on paclitaxel resistance and its inhibitory effect on cell migration and invasion abilities. Results showed that SAA significantly enhanced the sensitivity of MCF-7/PTX cells to paclitaxel and inhibited cell migration and invasion abilities. Cancer Biol Ther. 2015;16(9):1407-14
Human brain microvascular endothelial cells (HBMECs) 10 µM 6 hours To evaluate the protective effect of SAA on OGD-induced cell viability reduction and degradation of tight junction proteins. Results showed that SAA pretreatment significantly inhibited OGD-induced cell viability reduction and degradation of tight junction proteins (ZO-1, occludin, claudin-5). Acta Pharmacol Sin. 2021 Mar;42(3):370-381
A549 cells 6.461 µM (IC50) 72 hours Evaluate the inhibitory effect of Sal A on A549 cell proliferation, results showed Sal A significantly inhibited cell proliferation Int J Mol Sci. 2016 Aug 2;17(8):1244
DU145 cells 9.512 µM (IC50) 72 hours Evaluate the inhibitory effect of Sal A on DU145 cell proliferation, results showed Sal A significantly inhibited cell proliferation Int J Mol Sci. 2016 Aug 2;17(8):1244
HUVECs 20 µM 8 hours To evaluate the anti-angiogenesis effect of RGD-PEI/SAA complexes, results showed that the RGD-PEI/SAA treatment group exhibited the strongest anti-angiogenesis effect among all groups. J Nanobiotechnology. 2021 Jul 2;19(1):196

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague-Dawley rats MCT-induced pulmonary hypertension model by a single subcutaneous injection of MCT (60 mg/kg) Oral 0.3, 1, 3 mg/kg/day Once daily for 4 weeks SAA significantly attenuated pulmonary arterial remodeling in MCT-induced PAH rats, likely via activating the BMPRII-Smad pathway and inhibiting apoptosis. Acta Pharmacol Sin. 2016 Jun;37(6):772-82
Zucker diabetic fatty rats Type 2 diabetes mellitus with atherosclerosis induced by high-fat diet and Vitamin D3 injections Tail vein injection 1 mg/kg Once daily for 6 weeks To evaluate the therapeutic effects of Salvianolic acid A on type 2 diabetes mellitus with atherosclerosis. Results showed that SAA significantly reduced HbA1c levels, improved lipid disorders, reduced foam cells and cholesterol crystals in aortic tissues, and inhibited NLRP3 inflammasome activation and NF-κB signaling pathway. Molecules. 2020 Feb 28;25(5):1089
C57/BL6 mice Myocardial ischemia model Oral 10 mg/kg Once daily for one week To evaluate the protective effects of SAA and SAA-30 on myocardial ischemia, results showed that SAA-30 was more effective than SAA in improving myocardial ischemia symptoms EBioMedicine. 2018 Nov;37:246-258
SD rats Autologous thrombus stroke model Oral 10 mg/kg Twice daily for 5 days To evaluate the preventive effect of SAA on cerebrovascular endothelial injury caused by ischemic stroke. Results showed that SAA pretreatment significantly improved neurological deficits, intracerebral hemorrhage, BBB disruption, and vascular endothelial dysfunction. Acta Pharmacol Sin. 2021 Mar;42(3):370-381
Sprague-Dawley rats Intracerebral hemorrhage model Intraperitoneal injection 10 mg/kg Once daily for 5 days To evaluate the therapeutic effect of Salvianolic acid A on the intracerebral hemorrhage model in rats. Results showed that Salvianolic acid A significantly improved neurological deficits, reduced brain edema and hematoma volume, decreased iron deposition and neuronal degeneration, and inhibited ferroptosis by activating the Akt/GSK-3β/Nrf2 signaling pathway. Sci Rep. 2024 May 30;14(1):12427
Sprague-Dawley rats Electrocoagulation-induced autologous thrombus stroke model Intragastric administration 10 mg/kg Once daily for 14 days SAA administration significantly decreased infarction volume and vascular embolism, and ameliorated pathological injury in the hippocampus and striatum as well as the neurological deficits as compared with the model rats. Furthermore, SAA significantly promoted neural stem/progenitor cells (NSPCs) proliferation, migration and differentiation into neurons, enhanced axonal regeneration and diminished neuronal apoptosis around the ipsilateral subventricular zone (SVZ), resulting in restored neural density and reconstructed neural circuits in the ischemic striatum. Acta Pharmacol Sin. 2022 Sep;43(9):2212-2225
ApoE−/− mice Diabetic atherosclerosis model Oral gavage 10 mg/kg and 20 mg/kg Once daily for four weeks To investigate the effect of Salvianolic acid A on diabetic atherosclerosis. Results showed that SAA significantly reduced atherosclerotic plaque formation, inhibited pathological changes in the aorta, and ameliorated diabetic atherosclerosis by suppressing NLRP3 inflammasome activation and endothelial cell pyroptosis. Front Pharmacol. 2022 Nov 8;13:1009229
Sprague-Dawley rats Bile duct ligation (BDL)-induced liver fibrosis model Intragastric administration 10 mg/kg/day and 20 mg/kg/day Once daily for 3 weeks To investigate the effect of SalA on BDL-induced liver injury and fibrosis, results showed that SalA attenuated ER stress and liver fibrosis by up-regulating the SIRT1/HSF1 pathway Front Pharmacol. 2018 Nov 5;9:1277
Mice Diabetic myocardial ischemia-reperfusion injury model Intravenous injection 10 mg/kg/h Continuous infusion The combined application of low-dose propofol and salvianolic acid A conferred synergistic protective effects against myocardial ischemia-reperfusion injury in diabetes, superior to the use of high-dose propofol alone. Burns Trauma. 2024 Apr 9;12:tkad055
SD rats Gentamicin-induced AKI model and 5/6 nephrectomy-induced CKD model Intragastric administration 10, 20, 40 mg/kg/d 7 consecutive days (AKI model) or four weeks (CKD model) Salvianolic acid A improved gentamicin-induced AKI and 5/6 Nx-induced CKD, which may be achieved by inhibiting the release of inflammatory factors and alleviating oxidative stress injury, as well as regulating the MAPKs and TGF-β1/smads signaling pathways. Molecules. 2023 Apr 21;28(8):3630
C57BL/6 mice APAP-induced hepatotoxicity model Oral 15 mg/kg/day and 30 mg/kg/day Once daily for 3 days To evaluate the protective effect of Salvianolic acid A on APAP-induced hepatotoxicity, results showed that Salvianolic acid A significantly reduced serum ALT and AST levels and alleviated liver tissue damage. Antioxidants (Basel). 2023 Apr 3;12(4):870
BALB/c nude mice 4T1 breast cancer model Tail vein injection 2 mg/kg DOX and 20 mg/kg Sal A Once every two days, total of 6 administrations Evaluate the anti-tumor effect and nephrotoxicity of E-[c(RGDfK)2]/FA-NLC-Sal A/DOX, results showed the best anti-tumor effect (tumor volume inhibition rate 90.72%, tumor weight inhibition rate 83.94%) and low nephrotoxicity (serum creatinine concentration 52.58 μmoL/L) J Nanobiotechnology. 2022 Sep 24;20(1):425
Sprague-Dawley rats 5/6 nephrectomized rat model Intraperitoneal injection 2.5, 5, 10 mg/kg/day Once daily for 28 days To evaluate the protective effect of SAA on kidney injury in 5/6 nephrectomized rats. Results showed that SAA dose-dependently reduced the levels of urine protein, blood urea nitrogen, serum creatinine, plasma total cholesterol, and plasma triglycerides, and improved renal pathological lesions and fibrosis. Additionally, SAA inhibited the activation of NF-κB and p38 MAPK signaling pathways and reduced the secretion of inflammatory cytokines. Acta Pharmacol Sin. 2018 Dec;39(12):1855-1864
C57BL/6J mice Laser-induced choroidal neovascularization model Intravitreal injection 20 µM Single injection, observed for 7 days To evaluate the anti-angiogenesis effect of RGD-PEI/SAA complexes in a laser-induced CNV mouse model, results showed that the RGD-PEI/SAA treatment group reduced the CNV area by 55.78% compared to the PBS group. J Nanobiotechnology. 2021 Jul 2;19(1):196
C57BL/6J mice High-fat and high-carbohydrate diet-induced fatty liver model Intraperitoneal injection 20 and 40 mg/kg Every other day for 10 weeks To evaluate the protective effects of Salvianolic acid A against high-fat and high-carbohydrate diet-induced fatty liver. Results showed that Salvianolic acid A attenuated body weight gain, liver injury, and hepatic steatosis. Front Pharmacol. 2020 Nov 30;11:560905
Male C57BL/6 mice High-fat diet-induced obesity model Intraperitoneal injection 20 and 40 mg/kg Administered every other day for 13 weeks To investigate the protective anti-obesity mechanisms of Sal A, results showed that Sal A significantly attenuated weight gain and lipid accumulation, and induced browning of white adipose tissue Front Pharmacol. 2021 May 28;12:614406
BALB/c mice ATO-induced cardiotoxicity model Intraperitoneal injection 3 mg/kg Once daily for 2 weeks Sal A pretreatment alleviated ATO-induced cardiac mitochondrial damage Front Pharmacol. 2018 May 9;9:487
C57BL/6J mice High-fat diet-induced obese mouse model Intraperitoneal injection 40 mg/kg Every other day for 12 weeks To evaluate the protective effects of Salvianolic acid A against high-fat diet-induced myocardial injury. Results showed that Salvianolic acid A significantly improved myocardium morphological changes and myocardial damage, and reduced plasma AST and CK-MB levels. Front Pharmacol. 2021 Mar 8;12:627123
Sprague-Dawley rats CCl4-induced liver fibrosis model Intraperitoneal injection 5 mg/kg and 15 mg/kg Once daily for 6 weeks To evaluate the therapeutic effect of salvianolic acid A on CCl4-induced liver fibrosis. The results showed that salvianolic acid A significantly reduced the degree of liver fibrosis, improved liver function indicators, reduced collagen deposition, and inhibited hepatic stellate cell activation and hepatocyte apoptosis by inhibiting the PI3K/AKT/mTOR signaling pathway and regulating the Bcl-2/Bax and caspase-3/cleaved caspase-3 signaling pathways. Drug Des Devel Ther. 2019 May 31;13:1889-1900
BALB/c mice Pristane-induced systemic lupus erythematosus model Oral gavage 5 mg/kg/d Once daily for 5 months To evaluate the protective effect of salvianolic acid A on renal injury in pristane-induced systemic lupus erythematosus mice. The results showed that salvianolic acid A significantly reduced the levels of anti-Sm autoantibodies, alleviated renal histopathological changes, and significantly inhibited the phosphorylation of IKK, IκB and NFκB in renal tissues. Acta Pharm Sin B. 2017 Mar;7(2):159-166

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.02mL

0.40mL

0.20mL

10.11mL

2.02mL

1.01mL

20.22mL

4.04mL

2.02mL

References

 

Historical Records

Categories